Market Place
Sourcing Support
FDA Rejects Eylea HD For Ongoing Manufacturing Issues
29 Oct 2025 //
FIERCE PHARMA
Zag Bio Emerges With $80M Funding For Tregs Diabetes Candidate
29 Oct 2025 //
FIERCE BIOTECH
Regeneron Unveils Q3 2025 Financial Results
28 Oct 2025 //
GLOBENEWSWIRE
Regeneron Scraps 2Seventy`s CAR T For Lymphoma In Strategic Move
24 Oct 2025 //
BIOSPACE
Regeneron Does 180 On 2Seventy Lymphoma CAR-T
23 Oct 2025 //
FIERCE BIOTECH
Rising Stars: Kristen Raimondi On Creating New Hope For Patients
22 Oct 2025 //
FIERCE PHARMA
Regeneron, Celltrion Shake Hands On Eylea Biosimilar Settlement
22 Oct 2025 //
FIERCE PHARMA
Libtayo Recommended by CHMP for Adjuvant CSCC in EU
17 Oct 2025 //
GLOBENEWSWIRE
Regeneron, Sanofi Receive 1- To 2-Month Priority Review Vouchers
17 Oct 2025 //
FIERCE BIOTECH
Regeneron Shows Advances in Oncology Portfolio & Pipeline at ESMO
15 Oct 2025 //
GLOBENEWSWIRE
Novo Plant Issues May Mean Delays For Regeneron, Scholar Rock
13 Oct 2025 //
FIERCE PHARMA
DB-OTO Show Dramatic Hearing Improvements In Genetic Hearing Loss
12 Oct 2025 //
GLOBENEWSWIRE
FDA Expands Regeneron`s Libtayo Treatment for Skin Cancer
09 Oct 2025 //
REUTERS
Regeneron To Present Q3 2025 Results, Host Conference On Oct 28
30 Sep 2025 //
GLOBENEWSWIRE
Evkeeza Approval For Ultra-Rare Pediatric High Cholesterol
26 Sep 2025 //
GLOBENEWSWIRE
Sanofi`s Dupixent® For Chronic Spontaneous Urticaria Gains
22 Sep 2025 //
GLOBENEWSWIRE
Sanofi, Regeneron`s Dupixent For Chronic Spontaneous Urticaria
22 Sep 2025 //
GLOBENEWSWIRE
Regeneron Donates Ebola Treatment to High-Risk Countries
19 Sep 2025 //
GLOBENEWSWIRE
Regeneron`s Rare Bone Disorder Drug Succeeds in Late-Stage Trial
17 Sep 2025 //
REUTERS
Sanofi`s Libtayo Combo Shows 5-Year Survival Gain in NSCLC
16 Sep 2025 //
INDPHARMAPOST
Targeted Myasthenia Gravis Therapies Flood Sparse Market
15 Sep 2025 //
BIOSPACE
Sandoz to Launch Eylea Biosimilar in Late 2026 After Settlement
09 Sep 2025 //
FIERCE PHARMA
Libtayo Plus Chemo Shows 5-Year Survival in Advanced Lung Cancer
09 Sep 2025 //
GLOBENEWSWIRE
Regeneron Antibodies Triumph in Ph. 3 Cat, Pollen Allergy Trials
08 Sep 2025 //
FIERCE BIOTECH
Regeneron Adjusts Presentation Time at Investor Conference
04 Sep 2025 //
GLOBENEWSWIRE
Regeneron Plans 2026 FDA Filing for siRNA Myasthenia Gravis Drug
27 Aug 2025 //
BIOSPACE
Regeneron`s Immune Disorder Therapy Improves Functions in Trial
27 Aug 2025 //
REUTERS
Regeneron Reports Ph3 Success in Generalized Myasthenia Gravis
26 Aug 2025 //
GLOBENEWSWIRE
FDA Delays 2 Decisions on Eylea HD Due to Manufacturing Issues
21 Aug 2025 //
FIERCE PHARMA
Regeneron Announces Investor Conference Presentations
07 Aug 2025 //
GLOBENEWSWIRE
Onco360® to Partner as Specialty Pharmacy for Lynozyfic
04 Aug 2025 //
GLOBENEWSWIRE
FDA Declines to Approve Regeneron`s Blood Cancer Drug
02 Aug 2025 //
REUTERS
Regeneron Unveils Strong Q2 2025 Financial and Operating Results
01 Aug 2025 //
GLOBENEWSWIRE
Issues at Novo Nordisk`s Indiana site trip up Regeneron again
01 Aug 2025 //
FIERCE PHARMA
Regeneron Reveals 2025 Creative Innovation Prize Winners
24 Jul 2025 //
GLOBENEWSWIRE
US FDA Approves Regeneron`s Blood Cancer Therapy
04 Jul 2025 //
PRESS RELEASE
Regeneron`s Biologics Lynozyfic Receive Approval in US
02 Jul 2025 //
FDA
Regeneron to Report Q2 Results on August 1
26 Jun 2025 //
GLOBENEWSWIRE
Regeneron Launches Donation Matching Program with Charity
24 Jun 2025 //
GLOBENEWSWIRE
Regeneron Backs Off 23andMe, Losing Bid to Former CEO
17 Jun 2025 //
BIOSPACE
Dupixent Beats Xolair in Ph4 Nasal Polyp Study at EAACI 2025
15 Jun 2025 //
PRESS RELEASE
Regeneron Says Weight-Loss Drug Helped Preserve Muscle Mass
03 Jun 2025 //
REUTERS
Regeneron Expands Clinical-Stage Obesity Portfolio
02 Jun 2025 //
PRESS RELEASE
Libtayo Phase 3 Data in Adjuvant Treatment of High-Risk Carcinoma
31 May 2025 //
GLOBENEWSWIRE
Linvoseltamab Combos Show Early Results In R/R Myeloma
22 May 2025 //
GLOBENEWSWIRE
AI Genomics Breakthrough Aligns with Regeneron’s 23andMe Buyout
22 May 2025 //
GLOBENEWSWIRE
Viz.ai Collaborates With Sanofi and Regeneron on COPD Care
21 May 2025 //
PRESS RELEASE
Regeneron to Acquire 23andMe in Court-Supervised Sale
19 May 2025 //
GLOBENEWSWIRE
Regeneron plans to buy 23andMe for $256M
19 May 2025 //
ENDPTS
Amgen owes Regeneron $407M after defeat in PCSK9 antitrust suit
17 May 2025 //
FIERCE PHARMA
Teen Scientists Win $9M+ at 2025 Regeneron ISEF
16 May 2025 //
GLOBENEWSWIRE
Dupixent® Data at ATS Show Benefits in Type 2 Lung Inflammation
01 May 2025 //
GLOBENEWSWIRE
Regeneron to Highlight ASCO Advances with Libtayo Updates
01 May 2025 //
GLOBENEWSWIRE
Regeneron`s first-quarter results miss on lower Eylea demand
30 Apr 2025 //
REUTERS
After FDA rejection, Regeneron scores EU nod for Lynozyfic
29 Apr 2025 //
FIERCE PHARMA
Eylea HD® Injection 8 mg at ARVO Shows Safety and Efficacy
28 Apr 2025 //
GLOBENEWSWIRE
Lynozyfic (linvoseltamab) Approved in EU for Multiple Myeloma
28 Apr 2025 //
GLOBENEWSWIRE
Sanofi off to a promising start in launch of Dupixent for COPD
24 Apr 2025 //
FIERCE PHARMA
Regeneron to invest over $3 billion to boost US manufacturing
23 Apr 2025 //
PRESS RELEASE
Regeneron Announces Investor Conference Presentations
21 Apr 2025 //
GLOBENEWSWIRE
